Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
Back to Search Results

Connection

Search Results to Frits Van Rhee

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Van Rhee, Frits

Item TypeName
Academic Article DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
Academic Article Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.
Academic Article Predicting long-term survival in multiple myeloma patients following autotransplants.
Academic Article Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
Academic Article Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.
Academic Article Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.
Academic Article A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.
Academic Article Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.
Academic Article Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.
Academic Article The Arkansas approach to therapy of patients with multiple myeloma.
Academic Article A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
Academic Article Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?
Academic Article Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning.
Academic Article High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients.
Concept Patients
Academic Article The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation
Academic Article In vitro generation of Epstein-Barr virus-specific cytotoxic T cells in patients receiving haplo-identical allogeneic stem cell transplantation
Academic Article Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse
Academic Article Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha
Academic Article High-dose melphalan-based autotransplants for muliple myeloma: the Arkansas experience since 1989 in 3077 patients
Academic Article Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
Academic Article Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction
Academic Article Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission
Academic Article Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation
Academic Article Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.
Academic Article Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
Academic Article A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
Academic Article Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma.
Academic Article Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease.
Grant Potentiating Natural Killer Cell Anti-Myeloma Effects
Grant Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administered Intranodally in Multiple Myeloma Patients
Grant 2004-04: Treatment with AMD3100 in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Giv
Grant UARK 2003-41, A Phase II Study of High-Dose Density Therapy with Tandem Autologous Transplants for Patients with Multiple Myeloma
Grant KAG 301-Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (Kos 953) plus Bortezomib Compared to Bortezomib Alone in Patients with Multiple
Grant Qualitative Research in Castleman's Disease: Exploring Patients' Perspectives through Interviews, Project #A2-7438
Grant Phase 3 Randomized, open-label clinical trial of tanespimycin (KO953) plus Bortezomib Compared to bortezomib alone in patients with multiple myeloma i
Academic Article Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.
Academic Article BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma.
Academic Article Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
Grant S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct...260489
Academic Article Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
Academic Article Epigenetic Deregulation of Telomere-Related Genes in Newly Diagnosed Multiple Myeloma Patients.
Academic Article Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma.
Academic Article Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma.
Academic Article Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission.
Academic Article The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry.
Academic Article Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial.
Academic Article Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives.
Academic Article Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma.
Academic Article Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy.
Academic Article Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States.
Grant UARK 2003-41, A Phase II Study of High-Dose Density Therapy with Tandem Autologous Transplants for Patients with Multiple Myeloma
Grant Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administered Intranodally in Multiple Myeloma Patients
Grant Qualitative Research in Castleman's Disease: Exploring Patients' Perspectives through Interviews, Project #A2-7438
Grant UARK 2014-21: Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS with Cyclophosphamide in Patients with Recurrent or Refractory Multiple Myeloma
Academic Article Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients.
Academic Article Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines.
Academic Article The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
Academic Article Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
Academic Article Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems.
Academic Article A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation.

Search Criteria
  • Outpatients